Etracker Debug:
	et_pagename = "Clinical Chemistry and Laboratory Medicine (CCLM)|cclm|C|[EN]"
	
        
Jump to ContentJump to Main Navigation

Clinical Chemistry and Laboratory Medicine (CCLM)

Published in Association with the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM)

Editor-in-Chief: Plebani, Mario

Editorial Board Member: Gillery, Philippe / Kazmierczak, Steven / Lackner, Karl J. / Lippi, Giuseppe / Melichar, Bohuslav / Schlattmann, Peter / Whitfield, John B.

13 Issues per year

IMPACT FACTOR 2013: 2.955
Rank 5 out of 29 in category Medical Laboratory Technology in the 2013 Thomson Reuters Journal Citation Report/Science Edition

VolumeIssuePage

Issues

Mesothelin family proteins and diagnosis of mesothelioma: analytical evaluation of an automated immunoassay and preliminary clinical results

Francesca Di Serio1 / Antonietta Fontana2 / Michele Loizzi3 / Giuseppe Capotorto4 / Piera Maggiolini5 / Ernesto Mera6 / Lucia Bisceglia7 / Raffaele Molinini8

1Department of Clinical Pathology I, University Hospital of Bari, Bari, Italy

2Department of Clinical Pathology I, University Hospital of Bari, Bari, Italy

3Department of Thoracic Surgery, University Hospital of Bari, Bari, Italy

4Department of Thoracic Surgery, University Hospital of Bari, Bari, Italy

5Department of Clinical Pathology I, University Hospital of Bari, Bari, Italy

6Department of Occupational Medicine, University Hospital of Bari, Bari, Italy

7Section of Environmental and Occupational Epidemiology and Ergonomics, University Hospital of Bari, Bari, Italy

8Department of Occupational Medicine, University Hospital of Bari, Bari, Italy

Corresponding author: Francesca Di Serio, Department of Clinical Pathology I, University Hospital of Bari, Piazza Giulio Cesare N. 11, 70124 Bari, Italy Phone: +39-080-5592629, Fax: +39-080-5592124,

Citation Information: Clinical Chemical Laboratory Medicine. Volume 45, Issue 5, Pages 634–638, ISSN (Online) 14346621, ISSN (Print) 14374331, DOI: 10.1515/CCLM.2007.112, May 2007

Publication History

Received:
2006-11-23
Accepted:
2007-01-29
Published Online:
2007-05-07

Abstract

Background: Studies have suggested that soluble mesothelin-related protein (SMRP) can be used as a serum marker of malignant mesothelioma.

Methods: We assessed the analytical performance of the Mesomark (Fujirebio Diagnostic) two-step ELISA on an automated analyser and performed a preliminary clinical evaluation. The precision of the assay and the in vitro effect of interfering substances on SMRP concentrations were investigated. The serum marker was analysed in 109 healthy subjects never exposed to asbestos, 26 healthy subjects exposed to asbestos, 33 patients with asbestosis, 33 with asbestos-related pleural plaques, 10 with non-malignant pleural diseases, 30 with lung cancer and 24 with histological diagnosis of pleural mesothelioma.

Results: Using the International Mesothelioma Interest Group classification, there were nine stage IV, two stage III, four stage II and nine stage I patients. SMRP concentrations of 4.75, 11.0 and 14 nmol/mL showed a total imprecision of 3.5%, 3.1% and 3.8%. The detection limit was 0.035 nmol/mL; the mean SMRP concentration of 0.63 nmol/mL was associated with a coefficient of variation of 10%. There was no effect (p>0.05) of interfering substances. Serum samples from patients with established pleural mesothelioma had significantly higher (p<0.05) concentrations of SMRP than control healthy and patient groups.

Conclusions: SMRP measured on automated systems could be useful for the diagnosis of mesothelioma in routine clinical practice.

Clin Chem Lab Med 2007;45:634–8.

Keywords: mesothelioma; soluble mesothelin-related peptides

Comments (0)

Please log in or register to comment.
Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.